This Ivermectin Study could change EVERYTHING for fighting cancer

This episode of American Conservative University explores a groundbreaking preprint study on ivermectin and mebendazole in cancer treatment, highlighting a remarkable 84.4% clinical benefit rate among 200 cancer patients after six months of treatment. The study, led by epidemiologist Nicholas Holscher of the McCullough Foundation, reveals that nearly half of participants experienced tumor regression or complete disappearance, even in metastatic cases. The host and guest frame this as a potential paradigm shift in oncology, arguing that the biopharmaceutical and 'chemo cartel' suppressed evidence for decades—citing a declassified CIA document from the 1950s that acknowledged antiparasitic drugs' anti-tumor effects. The episode critiques the high cost and toxicity of chemotherapy, contrasting it with the low cost and safety of ivermectin and mebendazole, which target cancer stem cells, disrupt microtubules, and inhibit glucose metabolism in cancer cells. The discussion also touches on the potential link between parasitic infections and cancer development, advocating for annual parasite cleanses as a preventative measure, especially for those exposed to raw food or outdoor environments. Despite promising results, the need for large-scale, government-funded, double-blind clinical trials is emphasized to validate findings and overcome industry resistance. The episode concludes with a call to action: redirecting war funding toward cancer research and urging public awareness. Holscher provides multiple avenues for accessing the study, including preprint servers, his personal website, and social media. The tone is urgent and impassioned, blending scientific claims with political critique, and centers on the ethical imperative to make low-cost, effective treatments accessible. The host expresses deep sorrow over lives lost due to suppressed information, framing the study not just as medical breakthrough but as a moral reckoning.